Boston Scientific Corporation $BSX Stock: Curated Wealth Partners LLC Lowers Stake

Curated Wealth Partners LLC trimmed its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 97.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,347 shares of the medical equipment provider’s stock after selling 598,352 shares during the quarter. Curated Wealth Partners LLC’s holdings in Boston Scientific were worth $626,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. WealthPlan Investment Management LLC acquired a new position in shares of Boston Scientific in the 3rd quarter worth approximately $203,000. Mainsail Asset Management LLC bought a new stake in shares of Boston Scientific in the 3rd quarter valued at $234,000. Nvwm LLC boosted its stake in shares of Boston Scientific by 526.2% in the 3rd quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 542 shares during the last quarter. ZWJ Investment Counsel Inc. increased its position in shares of Boston Scientific by 25.3% during the third quarter. ZWJ Investment Counsel Inc. now owns 739,647 shares of the medical equipment provider’s stock worth $32,286,000 after buying an additional 149,431 shares during the period. Finally, Mather Group LLC. increased its position in shares of Boston Scientific by 74.7% during the third quarter. Mather Group LLC. now owns 18,131 shares of the medical equipment provider’s stock worth $831,000 after buying an additional 7,750 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on BSX shares. The Goldman Sachs Group lowered their target price on shares of Boston Scientific from $71.00 to $57.00 and set a “buy” rating for the company in a research note on Tuesday, July 14th. JPMorgan Chase & Co. dropped their target price on shares of Boston Scientific from $80.00 to $56.00 and set an “overweight” rating on the stock in a report on Thursday, July 30th. Truist Financial cut their price target on shares of Boston Scientific from $57.00 to $51.00 and set a “buy” rating on the stock in a research report on Wednesday. Stifel Nicolaus set a $60.00 price target on Boston Scientific in a report on Wednesday, July 29th. Finally, Jefferies Financial Group decreased their price target on Boston Scientific from $67.00 to $60.00 and set a “buy” rating for the company in a report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $68.23.

Insider Activity

In related news, Director David Habiger acquired 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael Mahoney purchased 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have purchased 194,522 shares of company stock worth $9,385,210. Company insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX opened at $44.17 on Friday. The firm has a market cap of $64.02 billion, a PE ratio of 17.88, a price-to-earnings-growth ratio of 1.04 and a beta of 0.58. Boston Scientific Corporation has a 52-week low of $41.38 and a 52-week high of $105.65. The business’s 50 day moving average price is $46.16 and its two-hundred day moving average price is $49.80. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 3.24 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.